Gastric Cancer

, Volume 21, Issue 4, pp 632–642 | Cite as

DEC1 is required for anti-apoptotic activity of gastric cancer cells under hypoxia by promoting Survivin expression

  • Yanfei Jia
  • Rui Hu
  • Ping Li
  • Yan Zheng
  • Yunshan Wang
  • Xiaoli Ma
Original Article



Human differentiated embryonic chondrocyte-expressed gene 1 (DEC1), which has been reported to be overexpressed in several types of cancer, is associated with tumorigenesis through participation in several biological processes. However, the complex mechanisms underlying DEC1 during carcinogenesis are controversial, and its roles in the development and malignancy of gastric cancer (GC) remain unclear.


We measured DEC1 expression in human GC cell lines. DEC1 levels in GC cells were downregulated by shRNA lentivirus infection. We also evaluated the effect of DEC1 downregulation on xenograft growth in vivo. The viability and apoptosis of the cells were assayed using the CCK8 assay and flow cytometry. The levels of DEC1, Survivin, and Bcl-2 were evaluated by Western blotting. Luciferase reporter was used to verify the downstream target of DEC1. The association of DEC1 and Survivin expression with prognosis was investigated by immunohistochemistry.


Downregulation of DEC1 inhibits GC cell proliferation in vitro and tumorigenicity in vivo. We observed that hypoxia-induced expression of DEC1 protects GC cells from apoptosis via transcriptional upregulation of Survivin. Furthermore, positive correlations between DEC1 with Survivin expression were observed in tissue sections from GC patients. Notably, GC patients with high expression levels of DEC1 and Survivin showed poor prognosis.


DEC1 acts as an anti-apoptotic regulator in GC cells under hypoxia by promoting Survivin expression. Our study demonstrates the critical role of the DEC1 in oncogenesis and highlights a novel role for DEC1 in the regulation of cell apoptosis in GC.


DEC1 Gastric cancer Anti-apoptosis Hypoxia Survivin 



This work was financially supported by the National Natural Science Foundation of China (Nos. 31671468 and 81602593), the Chinese Postdoctoral Science Foundation (No. 2016M602152), the Shandong Provincial Natural Science Foundation of China (Nos. 2016ZRA01062, ZR2015HM018 and ZR2012HM061), and the Jinan Postdoctoral Innovation Project (172634).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent statement

All study participants, or their legal guardian, provided informed written consent before study enrollment. The Ethics Committee of Jinan Cental Hospital approved this study.

Supplementary material

10120_2017_780_MOESM1_ESM.pptx (4 mb)
Supplementary material 1 (PPTX 4073 kb)


  1. 1.
    Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654–64.CrossRefPubMedGoogle Scholar
  2. 2.
    Shen M, Kawamoto T, Yan W, Nakamasu K, Tamagami M, Koyano Y, Noshiro M, Kato Y. Molecular characterization of the novel basic helix-loop-helix protein DEC1 expressed in differentiated human embryo chondrocytes. Biochem Biophys Res Commun. 1997;236:294–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Shen M, Yoshida E, Yan W, Kawamoto T, Suardita K, Koyano Y, Fujimoto K, Noshiro M, Kato Y. Basic helix-loop-helix protein DEC1 promotes chondrocyte differentiation at the early and terminal stages. J Biol Chem. 2002;277:50112–20.CrossRefPubMedGoogle Scholar
  4. 4.
    Honma S, Kawamoto T, Takagi Y, Fujimoto K, Sato F, Noshiro M, Kato Y, Honma K. Dec1 and Dec2 are regulators of the mammalian molecular clock. Nature (Lond). 2002;419:841–4.CrossRefGoogle Scholar
  5. 5.
    Sato F, Bhawal UK, Yoshimura T, Muragaki Y. DEC1 and DEC2 crosstalk between circadian rhythm and tumor progression. J Cancer. 2016;7:153–9.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    You J, Lin L, Liu Q, Zhu T, Xia K, Su T. The correlation between the expression of differentiated embryo-chondrocyte expressed gene l and oral squamous cell carcinoma. Eur J Med Res. 2014;19:21.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Liu Y, Miao Y, Wang J, Lin X, Wang L, Xu HT, Wang EH. DEC1 is positively associated with the malignant phenotype of invasive breast cancers and negatively correlated with the expression of claudin-1. Int J Mol Med. 2013;31:855–60.CrossRefPubMedGoogle Scholar
  8. 8.
    Chakrabarti J, Turley H, Campo L, Han C, Harris AL, Gatter KC, Fox SB. The transcription factor DEC1 (stra13, SHARP2) is associated with the hypoxic response and high tumour grade in human breast cancers. Br J Cancer. 2004;91:954–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Shi XH, Zheng Y, Sun Q, Cui J, Liu QH, Qu F, Wang YS. DEC1 nuclear expression: a marker of differentiation grade in hepatocellular carcinoma. World J Gastroenterol. 2011;17:2037–43.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Wang W, Reiser-Erkan C, Michalski CW, Raggi MC, Quan L, Yupei Z, Friess H, Erkan M, Kleeff J. Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Biochem Biophys Res Commun. 2010;401:422–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Liu Y, Wang L, Lin XY, Wang J, Yu JH, Miao Y, Wang EH. The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells. Tumour Biol. 2013;34:1641–50.CrossRefPubMedGoogle Scholar
  12. 12.
    Falvella FS, Colombo F, Spinola M, Campiglio M, Pastorino U, Dragani TA. BHLHB3: a candidate tumor suppressor in lung cancer. Oncogene. 2008;27:3761–4.CrossRefPubMedGoogle Scholar
  13. 13.
    Zhang L, Li QQ. Embryo-chondrocyte expressed gene 1, downregulating hypoxia-inducible factor 1 alpha, is another marker of lung tumor hypoxia. Acta Pharmacol Sin. 2007;28:549–58.CrossRefPubMedGoogle Scholar
  14. 14.
    Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Wykoff CC, Gatter KC, Harris AL. DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. J Pathol. 2003;200:222–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Jia YF, Xiao DJ, Ma XL, Song YY, Hu R, Kong Y, Zheng Y, Han SY, Hong RL, Wang YS. Differentiated embryonic chondrocyte-expressed gene 1 is associated with hypoxia-inducible factor 1alpha and Ki67 in human gastric cancer. Diagn Pathol. 2013;8:37.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Zheng Y, Jia Y, Wang Y, Wang M, Li B, Shi X, Ma X, Xiao D, Sun Y. The hypoxia-regulated transcription factor DEC1 (Stra13, SHARP-2) and its expression in gastric cancer. OMICS. 2009;13:301–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Zheng Y, Shi X, Wang M, Jia Y, Li B, Zhang Y, Liu Q, Wang Y. The increased expression of DEC1 gene is related to HIF-1alpha protein in gastric cancer cell lines. Mol Biol Rep. 2012;39:4229–36.CrossRefPubMedGoogle Scholar
  18. 18.
    Qiu GZ, Jin MZ, Dai JX, Sun W, Feng JH, Jin WL. Reprogramming of the tumor in the hypoxic niche: the emerging concept and associated therapeutic strategies. Trends Pharmacol Sci. 2017;38(8):669–86.CrossRefPubMedGoogle Scholar
  19. 19.
    Zeng W, Liu P, Pan W, Singh SR, Wei Y. Hypoxia and hypoxia inducible factors in tumor metabolism. Cancer Lett. 2015;356:263–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Li Y, Xie M, Yang J, Yang D, Deng R, Wan Y, Yan B. The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter. Oncogene. 2006;25:3296–306.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Chen X, Duan N, Zhang C, Zhang W. Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies. J Cancer. 2016;7:314–23.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Zhang S, Liu B, Fan Z, Wang D, Liu Y, Li J, Wang N, Liu Y, Zhang B. Targeted inhibition of survivin with YM155 promotes apoptosis of hypoxic human pulmonary arterial smooth muscle cells via the upregulation of voltage-dependent K(+) channels. Mol Med Rep. 2016;13:3415–22.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Harashima N, Takenaga K, Akimoto M, Harada M. HIF-2alpha dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression. Oncotarget. 2017;8(26):42887–900.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Chen YQ, Zhao CL, Li W. Effect of hypoxia-inducible factor-1alpha on transcription of survivin in non-small cell lung cancer. J Exp Clin Cancer Res. 2009;28:29.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ehata S, Hanyu A, Hayashi M, Aburatani H, Kato Y, Fujime M, Saitoh M, Miyazawa K, Imamura T, Miyazono K. Transforming growth factor-beta promotes survival of mammary carcinoma cells through induction of antiapoptotic transcription factor DEC1. Cancer Res. 2007;67:9694–703.CrossRefPubMedGoogle Scholar
  26. 26.
    Frigato E, Lunghi L, Ferretti ME, Biondi C, Bertolucci C. Evidence for circadian rhythms in human trophoblast cell line that persist in hypoxia. Biochem Biophys Res Commun. 2009;378:108–11.CrossRefPubMedGoogle Scholar
  27. 27.
    Guillaumond F, Lacoche S, Dulong S, Grechez-Cassiau A, Filipski E, Li XM, Levi F, Berra E, Delaunay F, Teboul M. Altered Stra13 and Dec2 circadian gene expression in hypoxic cells. Biochem Biophys Res Commun. 2008;369:1184–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Ivanov SV, Salnikow K, Ivanova AV, Bai L, Lerman MI. Hypoxic repression of STAT1 and its downstream genes by a pVHL/HIF-1 target DEC1/STRA13. Oncogene. 2007;26:802–12.CrossRefPubMedGoogle Scholar
  29. 29.
    Yamada K, Miyamoto K. Basic helix-loop-helix transcription factors, BHLHB2 and BHLHB3; their gene expressions are regulated by multiple extracellular stimuli. Front Biosci. 2005;10:3151–71.CrossRefPubMedGoogle Scholar
  30. 30.
    Miyazaki K, Kawamoto T, Tanimoto K, Nishiyama M, Honda H, Kato Y. Identification of functional hypoxia response elements in the promoter region of the DEC1 and DEC2 genes. J Biol Chem. 2002;277:47014–21.CrossRefPubMedGoogle Scholar
  31. 31.
    Vercherat C, Chung TK, Yalcin S, Gulbagci N, Gopinadhan S, Ghaffari S, Taneja R. Stra13 regulates oxidative stress mediated skeletal muscle degeneration. Hum Mol Genet. 2009;18:4304–16.CrossRefPubMedGoogle Scholar
  32. 32.
    Xiong J, Yang H, Luo W, Shan E, Liu J, Zhang F, Xi T, Yang J. The anti-metastatic effect of 8-MOP on hepatocellular carcinoma is potentiated by the down-regulation of bHLH transcription factor DEC1. Pharmacol Res. 2016;105:121–33.CrossRefPubMedGoogle Scholar
  33. 33.
    Li Y, Xie M, Song X, Gragen S, Sachdeva K, Wan Y, Yan B. DEC1 negatively regulates the expression of DEC2 through binding to the E-box in the proximal promoter. J Biol Chem. 2003;278:16899–907.CrossRefPubMedGoogle Scholar
  34. 34.
    Bhawal UK, Sato F, Arakawa Y, Fujimoto K, Kawamoto T, Tanimoto K, Ito Y, Sasahira T, Sakurai T, Kobayashi M, Kashima I, Kijima H, Kuniyasu H, Abiko Y, Kato Y, Sato S. Basic helix-loop-helix transcription factor DEC1 negatively regulates cyclin D1. J Pathol. 2011;224:420–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Ivanova AV, Ivanov SV, Zhang X, Ivanov VN, Timofeeva OA, Lerman MI. STRA13 interacts with STAT3 and modulates transcription of STAT3-dependent targets. J Mol Biol. 2004;340:641–53.CrossRefPubMedGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2017

Authors and Affiliations

  1. 1.Central LaboratoryJinan Central Hospital Affiliated to Shandong UniversityJinanPeople’s Republic of China
  2. 2.Department of ReproductionJinan Central Hospital Affiliated to Shandong UniversityJinanPeople’s Republic of China
  3. 3.Department of Clinical LaboratoryQilu Hospital of Shandong UniversityJinanPeople’s Republic of China
  4. 4.Shandong Province Key Lab of Tumor Target MoleculeJinan Central Hospital Affiliated to Shandong UniversityJinanPeople’s Republic of China

Personalised recommendations